Immunic Aktie [WKN DE: A2PHD4 / ISIN: US4525EP1011]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Immunic Inc Registered Shs

26.11.24		EQS-News: Immunic, Inc. to Participate in Investor Conference in December (EQS Group)
13.11.24		EQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology (EQS Group)
07.11.24		EQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update (EQS Group)
31.10.24		EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (EQS Group)
29.10.24		EQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in November (EQS Group)
22.10.24		Immunic Announces Positive Outcome From Interim Futility Analysis Of Phase 3 ENSURE Program (RTTNews)
22.10.24		EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis (EQS Group)
18.09.24		EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis (EQS Group)
04.09.24		EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome (EQS Group)
28.08.24		EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September (EQS Group)
08.08.24		EQS-News: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update (EQS Group)
01.08.24		EQS-News: Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update (EQS Group)
24.07.24		EQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (EQS Group)
05.01.24		Immunicto Privately Place Up To $240 Mln Of Shares; Stock Up In Pre-market (RTTNews)
21.11.23		Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis (PR Newswire)
02.11.23		Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts (PR Newswire)
26.10.23		Immunic to Participate in Scientific and Industry Conferences in November (PR Newswire)
16.10.23		Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 (PR Newswire)
15.10.23		Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 (PR Newswire)
11.10.23		Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting (PR Newswire)
10.10.23		Immunic Announces Positive Interim Data From Multiple Sclerosis Trial; Stock Surges (RTTNews)
09.10.23		Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
04.10.23		Immunic to Participate in Scientific Conferences in October (PR Newswire)
06.09.23		Immunic to Participate in Industry and Investor Conferences in September (PR Newswire)
17.08.23		Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
01.08.23		Immunic to Participate in Investor and Scientific Conferences in August (PR Newswire)
27.07.23		Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update (PR Newswire)
29.06.23		Immunic to Participate in Scientific and Investor Conferences in July (PR Newswire)
30.05.23		Immunic to Participate in Scientific and Investor Conferences in June (PR Newswire)
17.05.23		Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis (PR Newswire)
09.05.23		Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update (PR Newswire)
06.05.23		Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action (PR Newswire)
04.05.23		Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders (PR Newswire)
27.04.23		Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. (PR Newswire)
26.04.23		Immunic to Participate in Investor and Scientific Conferences in May (PR Newswire)
05.04.23		Immunic Announces Positive Data From Maintenance Phase Of CALDOSE-1 Study Of Vidofludimus Calcium UC (RTTNews)
05.04.23		Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis (PR Newswire)
02.03.23		Immunic to Participate in Investor and Scientific Conferences in March (PR Newswire)
22.02.23		Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 (PR Newswire)
16.02.23		Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update (PR Newswire)
09.02.23		Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need (PR Newswire)
25.01.23		Immunic to Participate in Scientific and Investor Conferences in February (PR Newswire)
17.11.22		Immunic : Data Show Encouraging Signals For Vidofludimus Calcium For Delaying Disability Worsening (RTTNews)
17.11.22		Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential (PR Newswire)
10.11.22		Immunic to Participate in Investor and Scientific Conferences in November and December (PR Newswire)
27.10.22		Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update (PR Newswire)
21.10.22		Pre-market Movers: IMUX, ARC, SNAP, VRE, JAN… (RTTNews)
20.10.22		Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate (PR Newswire)
17.10.22		Pre-market Movers: INPX, GEHI, HAPP, MPTI, ADEA… (RTTNews)
12.10.22		Pre-market Movers: SLS, CANG, HKD, GATO, CCJ… (RTTNews)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie bricht ein: KTM steht vor Insolvenz

MicroStrategy-Gründer als Fürsprecher: Microsoft will über Bitcoin-Investitionen abstimmen

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Trump-Drohungen belasten: US-Börsen schließen mit Gewinnen -- ATX beendet Handel im Minus -- DAX schließt schwächer -- Asiens Börsen beenden Handelstag mit Verlusten

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	29.11.2024 00:41
Kaufwert:	EUR
	Hinzufügen Speichern